Patents Assigned to INOVIO PHARMACEUTICALS, INC.
-
Patent number: 11925685Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.Type: GrantFiled: September 19, 2017Date of Patent: March 12, 2024Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Karuppiah Muthumani, Jian Yan
-
Patent number: 11865166Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.Type: GrantFiled: August 29, 2017Date of Patent: January 9, 2024Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Alfredo Perales Puchalt, Jian Yan, Anna Maria Slager
-
Patent number: 11851477Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.Type: GrantFiled: May 5, 2017Date of Patent: December 26, 2023Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Ami Patel, Jian Yan, Sarah Elliott
-
Patent number: 11845787Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation.Type: GrantFiled: March 27, 2018Date of Patent: December 19, 2023Assignees: The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Megan Wise
-
Patent number: 11844830Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: GrantFiled: January 5, 2021Date of Patent: December 19, 2023Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Jian Yan
-
Patent number: 11801288Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.Type: GrantFiled: April 9, 2021Date of Patent: October 31, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventor: Jian Yan
-
Patent number: 11801298Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.Type: GrantFiled: September 10, 2021Date of Patent: October 31, 2023Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Patent number: 11744885Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.Type: GrantFiled: May 14, 2021Date of Patent: September 5, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
-
Patent number: 11723840Abstract: Embodiments herein relate to the field of injections, for instance needle-free injections, and more specifically, to methods and apparatus for spring-driven intramuscular and intradermal injections. Provided in some embodiments are needle-free injectors adapted to deliver intradermal injections, as well as vial adaptors that are adapted to function as spacers when used with a needle-free injection device.Type: GrantFiled: October 25, 2019Date of Patent: August 15, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventors: Daniel E. Williamson, John R. Marshall
-
Patent number: 11684777Abstract: A method and device for electroporating adipocytes in the adipose layer of tissue, where the device includes a frame, a first electrode coupled to the frame having a first contact surface, a second electrode coupled to the frame having a second contact surface, and where the first contact surf ace and the second contact surface define a treatment zone therebetween. The method including positioning a fold of tissue between the first and second electrodes such that the treatment zone formed between the two electrodes includes an adipose layer of tissue and no skeletal muscle.Type: GrantFiled: September 22, 2017Date of Patent: June 27, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventors: Paul Fisher, Kate Broderick, Jay McCoy
-
Patent number: 11660335Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.Type: GrantFiled: February 25, 2021Date of Patent: May 30, 2023Assignees: Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and BiologyInventors: Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
-
Patent number: 11638747Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.Type: GrantFiled: December 17, 2018Date of Patent: May 2, 2023Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Jian Yan, Jewell Walters
-
Patent number: 11565107Abstract: A novel electroporation device for the delivery of vaccines that is both effective in generating a protective immune response and tolerable delivery to a subject (or near painless); and also methods of using same device to vaccinate a subject against a variety of infectious diseases and types of cancer in a near painless.Type: GrantFiled: March 1, 2011Date of Patent: January 31, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventors: Kate Broderick, Jay McCoy, Stephen V. Kemmerrer, Feng Lin, Rune Kjeken
-
Patent number: 11471675Abstract: An apparatus is provided for injecting a fluid into body tissue, the apparatus comprising: a hollow needle; and fluid delivery means, wherein the apparatus is adapted to actuate the fluid delivery means in use so as to automatically inject fluid into body tissue during insertion of the needle into the said body tissue.Type: GrantFiled: August 5, 2019Date of Patent: October 18, 2022Assignee: Inovio Pharmaceuticals, Inc.Inventors: Iacob Mathiesen, Torunn E. Tjelle, Knut Arvid Sorensen Rekdahl, Bjorn David-Andersen
-
Patent number: 11464841Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.Type: GrantFiled: September 29, 2017Date of Patent: October 11, 2022Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Jian Yan
-
Patent number: 11338029Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.Type: GrantFiled: December 13, 2018Date of Patent: May 24, 2022Assignee: Inovio Pharmaceuticals, Inc.Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
-
Patent number: 11338028Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen are disclosed. Methods of treating a subject with a LEMD1-expressing tumor and methods of preventing a LEMD1-expressing tumor are disclosed. Mutated consensus LEMD1 antigen is disclosed.Type: GrantFiled: December 13, 2018Date of Patent: May 24, 2022Assignee: Inovio Pharmaceuticals, Inc.Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
-
Patent number: 11331479Abstract: Described is a device and method for administration of molecules to tissue in vivo for various medical applications, the device comprising a single hypodermic injection needle and at least two spaced elongate electrodes which provide for the ability, when the needle is inserted into tissue, such as skin or muscle, to pulse tissue with a non-uniform electric field sufficient to cause reversible poration of cells lying along or in close proximity to the track made by the needle upon its insertion into said tissue.Type: GrantFiled: July 9, 2019Date of Patent: May 17, 2022Assignee: Inovio Pharmaceuticals, Inc.Inventors: Rune Kjeken, Iacob Mathiesen, Elisabeth Torunn Tjelle, George McHugh
-
Patent number: 11291827Abstract: An electroporation device having a battery pack including a plurality of battery cells and at least one lead in electrical communication with a circuit board. The battery pack including a safety switch and a controller for selectively placing the battery cells in electrical communication with the one lead. Where the controller is in operable communication with the safety switch such that when the controller detects one or more operating conditions the controller instructs the safety switch to electrically isolate the lead from the battery cells. The battery pack also includes a manual switch, and where activation of the switch causes the controller to instruct the safety switch to electrically isolate the lead from the battery cells.Type: GrantFiled: December 22, 2016Date of Patent: April 5, 2022Assignee: Inovio Pharmaceuticals. Inc.Inventors: Beat Stadelmann, Stephen Kemmerrer
-
Patent number: D987076Type: GrantFiled: July 2, 2020Date of Patent: May 23, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventors: Daniel E. Williamson, Andrew Bryan, Kevin Kemmerrer